Current Opinion in Pharmacology

Current Opinion in Pharmacology





Editors-in-Chief::T.P. Kenakin





Go to Journal Website

Personal Print Journal

Subscription Details

Estimated Delivery Time

In Stock

USD 336.00


Subscription Details

ScienceDirect Subscription

  • Access for 5 users
  • Access to 4 years of archives

USD 3,002.40

Print Journal

Subscription Details

Estimated Delivery Time

In Stock

USD 3,002.00
Buying for Institutions
Terms & Conditions

Additional Subscription Help


Aims & Scope

The Current Opinion journals were developed out of the recognition that it is increasingly difficult for specialists to keep up to date with the expanding volume of information published in their subject. In Current Opinion in Pharmacology, we help the reader by providing in a systematic manner:
1. The views of experts on current advances in pharmacology in a clear and readable form.
2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications

Division of the subject into sections
The subject of pharmacology is divided into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance.

NeurosciencesCardiovascular and renalRespiratoryMusculoskeletalCancerImmunomodulationAnti-infectives • New technologiesGastrointestinalEndocrine and metabolic diseases

Selection of topics to be reviewed
Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.

Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.

Editorial Overview
Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.

Ethics in Publishing: General Statement

The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

For more information, please refer to: click here


Academic and industrial pharmacologists, students and clinicians interested in advances in pharmacology.

Abstracting and Indexing

BIOSIS, CAB Abstracts, CAB Health, Chemical Abstracts, EMBASE, MEDLINE®, Scopus
Editors-in-Chief: N. Bowery Birmingham, UK, T.P. Kenakin Chapel Hill, NC, USA, Editorial Board: L. Annunziato Napoli, Italy, G. Bagetta Cosenza, Italy, D.C. Bertrand Genève, Switzerland, L.A. Blackshaw Adelaide SA, Australia, A. Bril Suresnes, France, J. Buckingham London, UK, G. Burnstock London, UK, H, Cox London, UK, M. Danhof Leiden, Netherlands, A. Davenport Cambridge, UK, S.J. Enna Kansas City, KS, USA, A. Feltz Paris, France, R.J. Flower London, UK, J. Furness Melbourne, VIC, Australia, S. Garattini Milan, Italy, T. Godfraind Brussels, Belgium, J. Gordon Birmingham, UK, G. Henderson Bristol, UK, B. Hirst Newcastle upon Tyne, UK, S. Johnston London, UK, J.K.C. Knowles Basel, Switzerland, O.A. Nedergaard Odense, Denmark, D.J. Nutt London, UK, C.P. Page London, UK, M. Perretti London, UK, J.P.R. Pin Montpellier, France, S. Projan Cambridge, MA, USA, U. Quast Tübingen, Germany, M. Rosenberg Madison, WI, USA, P. Soares-da-Silva Porto, Portugal, P.A. van Zwieten Amsterdam, Netherlands, P.M. Vanhoutte Hong Kong, China, E.S. Vizi Budapest, Hungary, M.J.O. Wakelam Cambridge, UK, S. Ward Bath, UK
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy

Contact Us

Author Services

Prepare your Article for submission
Translation Services
English Language Editing

Celebrate your publication success
Article Offprints, Journal Issues, Article/Cover Posters, Create Your Own Book

Additional Services
Mobile Apps,Special Content Offerings,and more...